COO
Price
$96.75
Change
-$1.03 (-1.05%)
Updated
Feb 23, 6:59 PM EST
4 days until earnings call
GMED
Price
$56.29
Change
+$1.01 (+1.83%)
Updated
Feb 23, 6:59 PM EST
67 days until earnings call
Ad is loading...

Analysis and predictions COO vs GMED

Header iconCOO vs GMED Comparison
Open Charts COO vs GMEDBanner chart's image
Cooper Companies (The)
Price$96.75
Change-$1.03 (-1.05%)
Volume$552.36K
CapitalizationN/A
Globus Medical
Price$56.29
Change+$1.01 (+1.83%)
Volume$450.37K
CapitalizationN/A
View a ticker or compare two or three
COO vs GMED Comparison Chart

Loading...

COODaily Signal changed days agoGain/Loss if shorted
 
Show more...
GMEDDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
COO vs. GMED commentary
Feb 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Buy and GMED is a Hold.

COMPARISON
Comparison
Feb 26, 2024
Stock price -- (COO: $96.75 vs. GMED: $56.29)
Brand notoriety: COO and GMED are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: COO: 378% vs. GMED: 110%
Market capitalization -- COO: $19.23B vs. GMED: $7.62B
COO [@Medical Specialties] is valued at $19.23B. GMED’s [@Medical Specialties] market capitalization is $7.62B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COO’s FA Score shows that 2 FA rating(s) are green whileGMED’s FA Score has 1 green FA rating(s).

  • COO’s FA Score: 2 green, 3 red.
  • GMED’s FA Score: 1 green, 4 red.
According to our system of comparison, COO is a better buy in the long-term than GMED.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COO’s TA Score shows that 5 TA indicator(s) are bullish while GMED’s TA Score has 5 bullish TA indicator(s).

  • COO’s TA Score: 5 bullish, 4 bearish.
  • GMED’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, COO is a better buy in the short-term than GMED.

Price Growth

COO (@Medical Specialties) experienced а +4.03% price change this week, while GMED (@Medical Specialties) price change was +4.59% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.94%. For the same industry, the average monthly price growth was +2.04%, and the average quarterly price growth was +3.78%.

Reported Earning Dates

COO is expected to report earnings on May 30, 2024.

GMED is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Medical Specialties (+1.94% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for COO with price predictions.
OPEN
A.I.dvisor published
a Summary for GMED with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
COO($19.2B) has a higher market cap than GMED($7.62B). COO has higher P/E ratio than GMED: COO (65.48) vs GMED (52.61). GMED YTD gains are higher at: 5.630 vs. COO (2.262). COO has higher annual earnings (EBITDA): 886M vs. GMED (347M). GMED has more cash in the bank: 518M vs. COO (399M). GMED has less debt than COO: GMED (520M) vs COO (2.57B). COO has higher revenues than GMED: COO (3.59B) vs GMED (1.57B).
COOGMEDCOO / GMED
Capitalization19.2B7.62B252%
EBITDA886M347M255%
Gain YTD2.2625.63040%
P/E Ratio65.4852.61124%
Revenue3.59B1.57B229%
Total Cash399M518M77%
Total Debt2.57B520M494%
FUNDAMENTALS RATINGS
COO vs GMED: Fundamental Ratings
COO
GMED
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
5067
SMR RATING
1..100
8686
PRICE GROWTH RATING
1..100
3247
P/E GROWTH RATING
1..100
2118
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GMED's Valuation (80) in the Medical Specialties industry is in the same range as COO (90). This means that GMED’s stock grew similarly to COO’s over the last 12 months.

COO's Profit vs Risk Rating (50) in the Medical Specialties industry is in the same range as GMED (67). This means that COO’s stock grew similarly to GMED’s over the last 12 months.

COO's SMR Rating (86) in the Medical Specialties industry is in the same range as GMED (86). This means that COO’s stock grew similarly to GMED’s over the last 12 months.

COO's Price Growth Rating (32) in the Medical Specialties industry is in the same range as GMED (47). This means that COO’s stock grew similarly to GMED’s over the last 12 months.

GMED's P/E Growth Rating (18) in the Medical Specialties industry is in the same range as COO (21). This means that GMED’s stock grew similarly to COO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COOGMED
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
50%
Bearish Trend 3 days ago
60%
Momentum
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
73%
MACD
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
61%
Bullish Trend 3 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
60%
Bullish Trend 3 days ago
63%
Advances
ODDS (%)
Bullish Trend 5 days ago
63%
Bullish Trend 3 days ago
66%
Declines
ODDS (%)
Bearish Trend 3 days ago
53%
Bearish Trend 13 days ago
58%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
61%
Bearish Trend 3 days ago
56%
Aroon
ODDS (%)
Bearish Trend 3 days ago
43%
Bullish Trend 3 days ago
64%
View a ticker or compare two or three
Ad is loading...
COODaily Signal changed days agoGain/Loss if shorted
 
Show more...
GMEDDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UTHY44.940.63
+1.42%
US Treasury 30 Year Bond ETF
KBWP102.320.39
+0.38%
Invesco KBW Property & Casualty Ins ETF
JVAL39.790.03
+0.08%
JPMorgan US Value Factor ETF
GSLC100.47N/A
N/A
Goldman Sachs ActiveBeta® US LgCp Eq ETF
SPRX24.42N/A
N/A
Spear Alpha ETF

COO and

Correlation & Price change

A.I.dvisor indicates that over the last year, COO has been loosely correlated with ALC. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then ALC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COO
1D Price
Change %
COO100%
-1.05%
ALC - COO
56%
Loosely correlated
-0.42%
ISRG - COO
55%
Loosely correlated
+0.18%
GMED - COO
53%
Loosely correlated
+1.86%
STE - COO
53%
Loosely correlated
-0.08%
TFX - COO
52%
Loosely correlated
+0.02%
More

GMED and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMED has been loosely correlated with KIDS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then KIDS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMED
1D Price
Change %
GMED100%
+1.86%
KIDS - GMED
50%
Loosely correlated
-0.14%
IDXX - GMED
49%
Loosely correlated
+0.87%
IART - GMED
47%
Loosely correlated
-0.27%
COO - GMED
44%
Loosely correlated
-1.05%
TMO - GMED
43%
Loosely correlated
+0.75%
More